aotccfteam.wordpress.com
December | 2011 |
https://aotccfteam.wordpress.com/2011/12
Archive for December, 2011. Question and Answer #1, Meghan Ramsay. AOTC program director, Meghan Ramsay, continues the conversation to ask a pertinent question. Meghan offers the 1st question from the symposium audience that wasn’t answered: Where does the VX-770 compound come from? Is it a natural occurring substance, and if so is it from a plant, fungus, etc? If not a plant how is it synthesized? Any thoughts on this? The Compound’s structure is represented as follows:. The John Hopkins University.
aotccfteam.wordpress.com
June | 2012 |
https://aotccfteam.wordpress.com/2012/06
Archive for June, 2012. Question From the Live Meeting. If I take Ivacaftor will I still need to take enzyme supplements or a high-calorie, high-fat diet? The John Hopkins University. School Of Medicine,. University School Of Medicine. An education grant from Vertex. Ahead of the Curve: Program Directory. Respiratory Medicine Resource Centre. AOTC: Genetics Revolution for the CF Care Team. Ahead of the Curve: Genetics Revolution for the CF Care Team. Blog at WordPress.com. Blog at WordPress.com.
aotccfteam.wordpress.com
September | 2012 |
https://aotccfteam.wordpress.com/2012/09
Archive for September, 2012. Question Six, From Michael Boyle, M.D., F.C.C.P. Are there potential problems with taking ivacaftor with my other cystic fibrosis medications? I think the answer has two parts. The first deals with interactions with CF medications and the second is along the lines of medications I don’t need to take. You should also avoid certain herbal medications such as St. John’s wort, because those can also affect how the liver will clear ivacaftor. The second part of your question, shou...
aotccfteam.wordpress.com
Question 4 |
https://aotccfteam.wordpress.com/2012/08/22/question-4
August 22, 2012. Will the new VX-809 trial attempt to increase the dosage of VX-809, since a dose response was so obvious? That seems likely. But let me first summarize the trial so far. The phase 2 trial combined VX-809 (lumacaftor) and VX-770 (ivacaftor; trade name Kalydeco) in doses ranging from 25 mg to 200 mg daily to determine whether the combination could improve lung function and reduce sweat chloride levels in patients with the most common cystic fibrosis mutation. Question from the Live Meeting.
aotccfteam.wordpress.com
Question from the Live Meeting |
https://aotccfteam.wordpress.com/2012/07/24/question-from-the-live-meeting-2
Question from the Live Meeting. July 24, 2012. These are gene-specific therapies, but many of our patients are not genotyped. Will there be programs available to help them with this process? So it sounds like with these therapies, the trend will be toward getting every patient genotyped, so that any patient who has access to this drug is able to take it. Plans are under way for a grant through the CF foundation to cover genotyping for not only uninsured patients, but basically for all ungenotyped patients.
aotccfteam.wordpress.com
March | 2012 |
https://aotccfteam.wordpress.com/2012/03
Archive for March, 2012. CF Care Team Journal Spotlight. As part of an ongoing effort to highlight new information in cystic fibrosis research, the CF Care Team will start highlighting a monthly peer reviewed journal. Review the journal here. And leave questions and comments on the blog for the CF Care Team! Http:/ thorax.bmj.com/content/67/1/4.extract. The John Hopkins University. School Of Medicine,. University School Of Medicine. An education grant from Vertex. Ahead of the Curve: Program Directory.
aotccfteam.wordpress.com
October | 2012 |
https://aotccfteam.wordpress.com/2012/10
Archive for October, 2012. CF Care Team Journal Spotlight. As part of an ongoing effort to highlight new information in cystic fibrosis research, the CF Care Team highlights a monthly peer reviewed journal. This month, Meghan Ramsay has selected Is cystic fibrosis genetic medicine’s canary? The article focuses on the rise and fall of gene therapy for CF and suggests that CF may provide a particularly compelling case study of a failed genomic technology. The John Hopkins University. School Of Medicine,.
aotccfteam.wordpress.com
CF Care Team Journal Spotlight |
https://aotccfteam.wordpress.com/2012/10/01/cf-care-team-journal-spotlight-3
CF Care Team Journal Spotlight. October 1, 2012. As part of an ongoing effort to highlight new information in cystic fibrosis research, the CF Care Team highlights a monthly peer reviewed journal. This month, Meghan Ramsay has selected Is cystic fibrosis genetic medicine’s canary? The article focuses on the rise and fall of gene therapy for CF and suggests that CF may provide a particularly compelling case study of a failed genomic technology. Http:/ www.ncbi.nlm.nih.gov/pubmed/21857124. Email check fail...
aotccfteam.wordpress.com
July | 2012 |
https://aotccfteam.wordpress.com/2012/07
Archive for July, 2012. Question from the Live Meeting. These are gene-specific therapies, but many of our patients are not genotyped. Will there be programs available to help them with this process? So it sounds like with these therapies, the trend will be toward getting every patient genotyped, so that any patient who has access to this drug is able to take it. The John Hopkins University. School Of Medicine,. University School Of Medicine. An education grant from Vertex. Blog at WordPress.com.
